OS likely to be higher since they have recently let it be known (through letters to shareholders) that Memorial Sloan Kettering and their lead researcher are now shareholders. My opinion of the arrangement with The Trout Group is that it's for investor awareness to help raise funding, not funding itself. Angiogenex now showing on The Trout Group's client page. Noteworthy, imo, that AGGX is the only non-reporting tradeable stock on their client list. Why would they raise investor awareness on a stock that can't be sold by investors? :)
I don't know their burn rate or how much cash they have on hand. I haven't asked them because if they answered me they'd be giving me inside information. My assumption here is that they have enough friendly investor backing to keep going without having to access the capital markets for cash or they wouldn't have gone "dark."
I'll keep holding, maybe adding in the hope that the connections noted above mean that major players in the field have confidence in Angiogenex. If the science works I'm expecting a return to SEC compliant status, an eventual move to NASDAQ, and a share price in dollars, not pennies. Dream on, as my friends tell me :)
News 
Market Data 
Discover 
